EPIX ESSA Pharma: Net earnings per share for the last 12 months

Public company logo of ESSA Pharma Inc (EPIX)

ESSA Pharma Inc. (EPIX) focuses on developing innovative inhibitors to combat resistant forms of prostate cancer. The current EPS TTM YoY growth rate captures this trend, with the 21.30 mark serving as the current metric. The issuer's financial stability depends directly on clinical trial results, while a strong team of biochemists and the involvement of specialized operators create the potential for a qualitative leap.

ESSA Pharma, Inc. (EPIX): Earnings per share for the last twelve months from 02/11/2024 to 02/20/2024

EPIX (ESSA Pharma, Inc.): analytical breakdowns and indicator data

- price and consensus price forecast:
Market Price ESSA Pharma|EPIX - Price Target Chart
- company stock capitalization data:
Market Valuation ESSA Pharma Inc|EPIX - Enterprise Value
- book capitalization data:
Net Asset Value per Share ESSA Pharma|EPIX - Company Book Value|Capitalization to Book Value Ratio essapharma.com|EPIX - Company Total Assets
- company total debt and liquidity indicators:
Debt to Capital ESSA Pharma Inc.|EPIX - Long-Term Debt to Equity|Short-Term Debt to Capital Coefficient ESSA Pharma|EPIX - Company Debts|Debts to Net Assets ESSA Pharma Inc|EPIX - Company Long-Term Debts|Company Short-Term Debts ESSA Pharma|Intermediate Coverage Ratio essapharma.com
- net income and valuation ratios data:
EPIX - Company Net Income|Forward Earnings ESSA Pharma Inc.|EPIX - P/E Multiple|Future Price to Earnings Multiple essapharma.com|EPIX - PEG Multiple|EV/EBITDA Multiple ESSA Pharma|EPIX - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year ESSA Pharma|EPIX - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months essapharma.com|EPIX - Earnings growth in current year|Earnings growth forecast for next year ESSA Pharma Inc.
- revenue and sales details:
EPIX - Company Sales|Company Future Revenue essapharma.com|EPIX - P/S Multiple|Market Cap to Expected Sales Ratio ESSA Pharma
Initial company analysis:EPIX (ESSA Pharma, Inc.)
Core merchandise of ESSA Pharma

ESSA Pharma Inc. (EPIX) is scaling the development of targeted oncology therapies through strategic partnerships and the acquisition of bioengineering patents. By analyzing the annual growth rate of EPS TTM, investors assess net income dynamics over a rolling year, which helps determine the efficiency of capitalizing scientific achievements and the company's ability to generate revenue to service obligations during a period of tight Fed monetary policy.

Competitor analysis for ESSA Pharma Inc.

Net earnings per one share for the last twelve months Merus NV|Immutep Corp (IMMP) - Earnings per share for the last twelve months|Net earnings per share for the last 12 months Anixa Biosciences Inc|ATOS (Atossa Therapeutics Inc) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months contexttherapeutics.com CNTX|Earnings per share for the last twelve months Mersana (MRSN)|BriaCell - Earnings per share for the last 12 months|QT Imaging - Net earnings per share for the last 12 months